Is Adaptive Biotechnologies Stock a Good Investment?
Adaptive Biotechnologies Investment Advice | ADPT |
- Examine Adaptive Biotechnologies' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Adaptive Biotechnologies' leadership team and their track record. Good management can help Adaptive Biotechnologies navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Life Sciences Tools & Services space and any emerging trends that could impact Adaptive Biotechnologies' business and its evolving consumer preferences.
- Compare Adaptive Biotechnologies' performance and market position to its competitors. Analyze how Adaptive Biotechnologies is positioned in terms of product offerings, innovation, and market share.
- Check if Adaptive Biotechnologies pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Adaptive Biotechnologies' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Adaptive Biotechnologies Corp stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Adaptive Biotechnologies Corp is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Adaptive Biotechnologies Stock
Researching Adaptive Biotechnologies' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 94.0% of the company shares are held by institutions such as insurance companies. The book value of Adaptive Biotechnologies was presently reported as 1.52. The company recorded a loss per share of 1.34. Adaptive Biotechnologies had not issued any dividends in recent years.
To determine if Adaptive Biotechnologies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Adaptive Biotechnologies' research are outlined below:
| Adaptive Biotechnologies had very high historical volatility over the last 90 days | |
| Adaptive Biotechnologies has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 170.28 M. Net Loss for the year was (225.25 M) with loss before overhead, payroll, taxes, and interest of (13.66 M). | |
| Adaptive Biotechnologies Corp currently holds about 383.74 M in cash with (156.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69. | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Hepion Pharmaceuticals faces Nasdaq delisting risk |
Adaptive Biotechnologies Quarterly Cash And Short Term Investments |
|
Adaptive Biotechnologies uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Adaptive Biotechnologies Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Adaptive Biotechnologies' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Adaptive Biotechnologies' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Adaptive Biotechnologies' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-02-26 | 2019-12-31 | -0.2 | -0.17 | 0.03 | 15 | ||
2021-02-24 | 2020-12-31 | -0.29 | -0.33 | -0.04 | 13 | ||
2020-05-12 | 2020-03-31 | -0.2 | -0.25 | -0.05 | 25 | ||
2022-11-03 | 2022-09-30 | -0.38 | -0.32 | 0.06 | 15 | ||
2022-08-03 | 2022-06-30 | -0.43 | -0.37 | 0.06 | 13 | ||
2024-11-07 | 2024-09-30 | -0.29 | -0.22 | 0.07 | 24 | ||
2023-02-14 | 2022-12-31 | -0.35 | -0.28 | 0.07 | 20 | ||
2021-08-04 | 2021-06-30 | -0.43 | -0.35 | 0.08 | 18 |
Know Adaptive Biotechnologies' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Adaptive Biotechnologies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adaptive Biotechnologies Corp backward and forwards among themselves. Adaptive Biotechnologies' institutional investor refers to the entity that pools money to purchase Adaptive Biotechnologies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 2.7 M | State Street Corp | 2024-06-30 | 2.5 M | Blue Water Life Science Advisors, Llc | 2024-09-30 | 2.1 M | Soleus Capital Management, L.p. | 2024-06-30 | 1.7 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.7 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.4 M | Pier Capital, Llc | 2024-09-30 | 1.3 M | Bank Of America Corp | 2024-06-30 | 1.1 M | Goldman Sachs Group Inc | 2024-06-30 | 1 M | Viking Global Investors Lp | 2024-09-30 | 30 M | Rubric Capital Management Lp | 2024-06-30 | 14 M |
Adaptive Biotechnologies' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 692.15 M.Market Cap |
|
Adaptive Biotechnologies' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.40) | (0.42) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.73) | (0.69) |
Determining Adaptive Biotechnologies' profitability involves analyzing its financial statements and using various financial metrics to determine if Adaptive Biotechnologies is a good buy. For example, gross profit margin measures Adaptive Biotechnologies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Adaptive Biotechnologies' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Adaptive Biotechnologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Adaptive Biotechnologies Corp. Check Adaptive Biotechnologies' Beneish M Score to see the likelihood of Adaptive Biotechnologies' management manipulating its earnings.
Evaluate Adaptive Biotechnologies' management efficiency
Adaptive Biotechnologies has return on total asset (ROA) of (0.1637) % which means that it has lost $0.1637 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6676) %, meaning that it created substantial loss on money invested by shareholders. Adaptive Biotechnologies' management efficiency ratios could be used to measure how well Adaptive Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.44 in 2024. Return On Capital Employed is likely to drop to -0.42 in 2024. At this time, Adaptive Biotechnologies' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 276.3 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 84.7 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.14 | 2.18 | |
| Tangible Book Value Per Share | 1.28 | 1.26 | |
| Enterprise Value Over EBITDA | (4.61) | (4.84) | |
| Price Book Value Ratio | 2.29 | 2.41 | |
| Enterprise Value Multiple | (4.61) | (4.84) | |
| Price Fair Value | 2.29 | 2.41 | |
| Enterprise Value | 871.8 M | 828.3 M |
Effective leadership at Adaptive Biotechnologies drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta 1.447 |
Basic technical analysis of Adaptive Stock
As of the 25th of November, Adaptive Biotechnologies shows the mean deviation of 3.69, and Risk Adjusted Performance of 0.0416. Adaptive Biotechnologies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Adaptive Biotechnologies' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adaptive Biotechnologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adaptive Biotechnologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adaptive Biotechnologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adaptive Biotechnologies' Outstanding Corporate Bonds
Adaptive Biotechnologies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Adaptive Biotechnologies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Adaptive bonds can be classified according to their maturity, which is the date when Adaptive Biotechnologies Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| ADAPTHEALTH LLC 6125 Corp BondUS00653VAA98 | View | |
| AdaptHealth LLC 4625 Corp BondUS00653VAC54 | View | |
| US00653VAE11 Corp BondUS00653VAE11 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Adaptive Biotechnologies' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Adaptive Biotechnologies' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0416 | |||
| Market Risk Adjusted Performance | 0.0812 | |||
| Mean Deviation | 3.69 | |||
| Semi Deviation | 3.69 | |||
| Downside Deviation | 3.92 | |||
| Coefficient Of Variation | 2319.15 | |||
| Standard Deviation | 5.22 | |||
| Variance | 27.22 | |||
| Information Ratio | 0.0181 | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.61) | |||
| Sortino Ratio | 0.024 | |||
| Treynor Ratio | 0.0712 | |||
| Maximum Drawdown | 31.46 | |||
| Value At Risk | (7.87) | |||
| Potential Upside | 9.71 | |||
| Downside Variance | 15.4 | |||
| Semi Variance | 13.59 | |||
| Expected Short fall | (4.74) | |||
| Skewness | 1.45 | |||
| Kurtosis | 4.26 |
| Risk Adjusted Performance | 0.0416 | |||
| Market Risk Adjusted Performance | 0.0812 | |||
| Mean Deviation | 3.69 | |||
| Semi Deviation | 3.69 | |||
| Downside Deviation | 3.92 | |||
| Coefficient Of Variation | 2319.15 | |||
| Standard Deviation | 5.22 | |||
| Variance | 27.22 | |||
| Information Ratio | 0.0181 | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.61) | |||
| Sortino Ratio | 0.024 | |||
| Treynor Ratio | 0.0712 | |||
| Maximum Drawdown | 31.46 | |||
| Value At Risk | (7.87) | |||
| Potential Upside | 9.71 | |||
| Downside Variance | 15.4 | |||
| Semi Variance | 13.59 | |||
| Expected Short fall | (4.74) | |||
| Skewness | 1.45 | |||
| Kurtosis | 4.26 |
Consider Adaptive Biotechnologies' intraday indicators
Adaptive Biotechnologies intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Adaptive Biotechnologies stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Adaptive Biotechnologies Corporate Filings
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 13th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Adaptive Stock media impact
Far too much social signal, news, headlines, and media speculation about Adaptive Biotechnologies that are available to investors today. That information is available publicly through Adaptive media outlets and privately through word of mouth or via Adaptive internal channels. However, regardless of the origin, that massive amount of Adaptive data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Adaptive Biotechnologies news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Adaptive Biotechnologies relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Adaptive Biotechnologies' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Adaptive Biotechnologies alpha.
Adaptive Biotechnologies Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Adaptive Biotechnologies can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Adaptive Biotechnologies Corporate Management
| Stacy JD | General VP | Profile | |
| Stacy Taylor | General VP | Profile | |
| Yi Zhou | Chief Officer | Profile | |
| Tycho Peterson | Chief Officer | Profile | |
| Kyle Piskel | Principal Officer | Profile | |
| Susan Bobulsky | Chief MRD | Profile |
Already Invested in Adaptive Biotechnologies Corp?
The danger of trading Adaptive Biotechnologies Corp is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adaptive Biotechnologies is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adaptive Biotechnologies. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adaptive Biotechnologies is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.